Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of quinazoline derivatives and n-benzylpiperidines. It has been studied as an experimental drug candidate with potential biological activities including enzyme inhibition. Notably, it acts as a potent inhibitor of m7GpppX diphosphatase (also known as scavenger decapping enzyme DcpS), with nanomolar affinity. It also shows weak inhibitory activity against cytochrome P450 2D6 and dihydrofolate reductase in vitro. The compound has not been approved for any therapeutic use and is primarily used in research settings to study RNA metabolism and related cellular processes. No clinical trials or approved indications are reported for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine.